1 patient with advanced or metastatic cancer that be refractory to standard therapy relapse after standard therapy or have no standard therapy that induce a complete response of at least 10 or improves survival by at least three month in addition patient with disease that be benign by pathology but relentlessly progressive lead to disability pain and premature death in the majority of case include but not limit to lymphangioleiomyomatosis lam type 2 neurofibromatosis nf erdheim chester disease and castleman 's disease may also be consider for enrollment 